Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
HyperpathiaTranscription factor JunP05412T6908525806604
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
Grimacing17.02.05.0290.000469%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Respiratory tract infection22.07.07.001; 11.01.08.017--Not Available
Unevaluable event08.01.03.051--Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.010--Not Available
Vascular stent thrombosis08.07.05.002; 24.04.02.023--Not Available
Breakthrough pain16.32.03.016; 08.01.08.0260.001171%Not Available
Urethral stenosis20.07.03.003--Not Available
Cardiovascular insufficiency24.06.03.005; 02.01.01.011--Not Available
Hyperpathia17.02.07.015--Not Available
Bronchial hyperreactivity22.03.01.0160.000367%Not Available
Substance abuse19.07.02.0060.003514%Not Available
Sphincter of Oddi dysfunction09.02.02.004; 07.18.02.0020.000937%Not Available
Treatment failure08.06.01.017--Not Available
Liver injury12.01.02.003; 09.01.07.022--Not Available
Regurgitation07.01.07.0040.000469%Not Available
Genital swelling21.10.01.010--Not Available
Brain injury19.07.03.007; 17.11.01.0030.000672%Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Kounis syndrome24.04.04.020; 10.01.03.037; 02.02.02.0200.000469%Not Available
Acute kidney injury20.01.03.016--
Bladder dysfunction20.03.03.0020.000469%Not Available
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.000733%Not Available
Posterior reversible encephalopathy syndrome17.13.02.0070.002577%
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000469%Not Available
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 23.03.05.005--Not Available
Medication residue present13.15.01.0320.008669%Not Available
The 19th Page    First    Pre   19 20 21    Next   Last    Total 21 Pages